Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Electromedical Technologies, Inc. (OTCQB:EMED). The Company is a pioneer in the development and manufacturing of bioelectronic devices, a multi-billion-dollar industry. This report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download it in its entirety, please visit https://bit.ly/36KMOrb.
Electromedical Technologies, Inc. has been developing and manufacturing bioelectronics products since 2004 and to date over $11 million worth of the Company’s current bioelectric device used to treat chronic and acute pain have been sold. Electromedical’s offering is non-invasive, non-toxic and effective. According to Mizhou Securities USA, the estimated pain prescription market alone is $24 billion. Thus, the opportunity looms large for sufferers seeking to migrate to alternative, effective therapies for chronic pain.
In the Opportunity Research report, analyst Rob Goldman discusses the potential of the Company’s new bioelectronic device under development for broad-based pain management and how it may potentially be used as a replacement for pharmaceuticals such as opioids.
Goldman noted, “The Company plans to introduce a smaller wearable version of its flagship product that can be used anywhere and comes at a very affordable price for consumers seeking effective treatments for pain. Moreover, the new WellnessPro POD is being designed with an established link between doctors and patients through a remote portal. This should allow doctors to actively monitor progress and modify treatments in real time, a novel telemedicine feature.”
“The new form factor and substantially reduced price should result in meaningful sales adoption and growth upon introduction. Sales are expected to come from the existing customer base as well as those seeking alternatives to pharmaceuticals such as opioids. Moreover, the new monthly subscription service model should provide valuable recurring revenue to Electromedical,” continued Goldman.
“Leveraging its FDA-cleared flagship’s technology and innovative financial model, we forecast revenue could reach $17 million in 2022, following a late 2021 launch. Based on a valuation comparison with its peer group, the shares appear very undervalued. Still, our 12-month price target reflects a reasonable price/revenue multiple, which reflects a big discount to nearly all of its publicly-traded peers. If the Company achieves our projected growth trajectory it could be afforded a substantially greater valuation,” Goldman concluded.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published company report on Electromedical Technologies, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Electromedical Technologies, Inc. (“the Company”). The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. A Speculative Buy rating for our covered companies is defined as a company that we believe exhibits the potential to generate outsized returns despite inherent, above-average business, market, or financial risk. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was compensated $4000 by a third party for the production and distribution of the research report and associated press release and distribution.
Media Contact
Company Name: Goldman Small Cap Research
Contact Person: Rob Goldman
Email: rob@goldmanresearch.com
Phone: 410-609-7100
City: Wichita
State: KS
Country: United States
Website: https://www.goldmanresearch.com